Expression differences of miR-142-5p between treatment-naïve chronic myeloid leukemia patients responding and non-responding to imatinib therapy suggest a link to oncogenic ABL2, SRI, cKIT and MCL1 signaling pathways critical for development of therapy resistanceTheresa Klümper, Ingolf Cascorbi|Experimental Hematology and Oncology|2020Cited by 36